Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

aspen pharma trading limited - analoghi della purina - analoghi della purina

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - azatioprina - azatioprina

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - daunorubicini hydrochloridum - polvere per concentrato per soluzione per infusione - daunorubicini hydrochloridum 20 mg, mannitolum, pro vitro. - remissionsinduktion bei akuten lymphoblastischen bzw. lymphatischen (all) und bei akuten myeloischen leukämien (aml). - synthetika

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - azatioprina - azatioprina

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - azatioprina - azatioprina

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - azathioprinum - compresse rivestite con film - azathioprinum 75 mg, cellulosum microcristallinum, silica colloidalis anhydrica, natrii stearylis fumaras, carmellosum natricum conexum, amylum pregelificatum, povidonum k 25, lactosum monohydricum 86.85 mg, Überzug: poly(alcohol vinylicus), talcum, macrogolum, polysorbatum 80, pro compresso obducto corresp. natrium 1.54 mg. - immunsuppressivum - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - azathioprinum - compresse rivestite con film - azathioprinum 100 mg, cellulosum microcristallinum, silica colloidalis anhydrica, natrii stearylis fumaras, carmellosum natricum conexum, amylum pregelificatum, povidonum k 25, lactosum monohydricum 115.8 mg, Überzug: poly(alcohol vinylicus), talcum, macrogolum, polysorbatum 80, pro compresso obducto corresp. natrium 2.06 mg. - immunsuppressivum - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - azathioprinum - filmtalbetten - azathioprinum 50 mg, cellulosum microcristallinum, silica colloidalis anhydrica, natrii stearylis fumaras, carmellosum natricum conexum, amylum pregelificatum, povidonum k 25, lactosum monohydricum 57.9 mg, Überzug: poly(alcohol vinylicus), talcum, macrogolum, polysorbatum 80, pro compresso obducto corresp. natrium 1.03 mg. - immunsuppressivum - synthetika

Unia Europejska - włoski - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - reiezione del trapianto - immunosoppressori - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

alfasigma s.p.a. - mesalazina (5-asa) - mesalazina (5-asa)